Skip to Content
MilliporeSigma
All Photos(1)

Documents

144M-9

Sigma-Aldrich

CD44 (MRQ-13) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-13, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (144M-94)
vial of 0.5 mL concentrate (144M-95)
bottle of 1.0 mL predilute (144M-97)
vial of 1.0 mL concentrate (144M-96)
bottle of 7.0 mL predilute (144M-98)

manufacturer/tradename

Cell Marque

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG2a

control

benign urothelium

shipped in

wet ice

storage temp.

2-8°C

visualization

membranous

Gene Information

human ... CD44(960)

General description

The CD44 family of glycoproteins exists in a number of variant isoforms, the most common being the standard 85-95kD or hematopoietic variant (CD44s) that is found in mesodermal cells such as hematopoietic, fibroblastic, and glial cells, and in some carcinoma cell lines. Higher molecular weight isoforms have been described in epithelial cells (CD44v) and are thought to function in intercellular adhesion and stromal binding. While the other functions and distributions of the CD44 family have not yet been completely elucidated they are also known to participate in embryonic development and angiogenesis as well as other molecular processes associated with specific adhesions, signal transduction, and cell migration. The recent demonstration of a concordance of the cell proliferation nuclear antigen, Ki-67, and CD44 expression in adenomatous polyps, colonic carcinomas and adjacent mucosa raises the possibility of involvement of CD44 in stimulating cell growth. It appears that the CD44-hyaluronate interaction is central to tumor invasiveness; the receptor allowing the uptake and subsequent degradation of metrical hyaluronate. While many human tumors express CD44, a positive correlation between increased CD44v expression and tumor progression and/or dedifferentiation has been demonstrated in only some. Such tumors include non-Hodgkin′s lymphoma (Stauder et al, 1995), hepatocellular carcinoma (Matthew et al, 1996), breast carcinoma, renal cell carcinoma (terpe et al, 1993), colonic carcinoma (Abassi et al, 1993; Wielenga et al, 1993; Herrlich et al, 1995) and some soft tissue tumors (Wand et al, 1996). More recent additions to the list include metastatic melanoma (Sviatoha, et al, 2002), prostatic carcinoma (Ekici et al, 2002), and gastric cancer (Yamaguchi et al, 2002). Conversely, CD44v expression is downgraded in other tumors including neuroblastoma (Shtivelman & Bisho, 1991), squamous cell and basal cell carcinomas of the skin (Herold-Mende et al, 1996). The suggestion that there is a positive association between CD44 isoform expression and progression in human tumors has important implications for diagnosis and prognosis. Unfortunately, the situation is not yet clear-cut. Confusion over the complicated exon boundaries together with the different nomenclature employed by researchers have added to problems of identifying the true metastasis-associated isoforms. Furthermore, stromal cells may contribute to the isoform pattern detected. Probably the most practical application of CD44 immunostaining at present is the discrimination of urothelial transitional call carcinoma-in-situ from non-neoplastic changes in the urothelium (McKenney JK, et al. 2001).

Quality


IVD

IVD

IVD

RUO

Linkage

CD44 Positive Control Slides, Product No. 144S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

H A H Gadalla et al.
BJU international, 93(1), 151-155 (2003-12-18)
To investigate the expression of CD44 protein in bilharzial and non-bilharzial bladder carcinomas, and to relate the results of immunohistochemistry to the established prognostic factors, as studies clearly show that altered adhesive function of tumour cells is important in the
CD44 and its role in tumour progression and metastasis.
J A East et al.
European journal of cancer (Oxford, England : 1990), 29A(14), 1921-1922 (1993-01-01)
A M Abbasi et al.
European journal of cancer (Oxford, England : 1990), 29A(14), 1995-2002 (1993-01-01)
Flash-frozen biopsies obtained from surgical specimens of three adenomatous polyps and 22 colorectal adenocarcinomas (19 primary and three metastatic) were tested by immunohistochemistry for CD44 expression using F10-44-2 monoclonal antibody. CD44 positivity was correlated with proliferative status defined by Ki-67
Cheng-Keng Chuang et al.
Anticancer research, 23(6C), 4635-4639 (2004-02-26)
Certain splice variants (CD44v) can promote the progressive and metastatic behavior of cancer. We tested whether different CD44v molecules were selectively expressed in transitional cell carcinomas based on the stage and grade. A panel of 13 TCC cell lines with
Sinan Ekici et al.
The Journal of urology, 167(5), 2037-2041 (2002-04-17)
A third of the patients treated with radical prostatectomy experience progression even when tumors are confined pathologically to the prostate. CD44 may be a promising prognostic marker for determining malignant potential. However, there has not been a standard scoring system

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service